Maruti Suzuki Q1 Standalone Revenue Rises to ₹52,456 Crore, Net Profit Declines 11%
Maruti Suzuki delivered robust Q1 FY27 standalone revenue growth of ≈36.6% YoY to ₹52,456 crore, while standalone net profit declined by ≈9.65% YoY to ₹3,352 crore due to margin contraction. Operating EBITDA margin dropped to 8.22% from 10.4% in Q1 FY26, highlighting raw material cost pressures despite high volume growth. The board also approved ₹561 crore of capital expenditure for setting up four compressed biogas projects in the first phase.
Market snapshot: Maruti Suzuki India Limited has reported its financial results for Q1 FY27, showcasing a strong top-line momentum but facing near-term margin pressure. Standalone revenue from operations grew robustly by ≈36.6% YoY to ₹52,456 crore, driven by resilient passenger vehicle sales volumes. However, standalone net profit declined by ≈9.65% YoY to ₹3,352 crore as rising input costs and higher promotional expenses compressed operating margins.
Data Snapshot
- Standalone revenue from operations reached ₹52,456 crore in Q1 FY27, up ≈36.6% YoY.
- Standalone net profit for the quarter stood at ₹3,352 crore, down ≈9.65% YoY.
- Standalone operating EBITDA reached ₹4,311 crore, up ≈7.91% YoY.
- EBITDA margin contracted by 218 basis points YoY to 8.22%.
- The board approved a capital outlay of ₹561 crore for four compressed biogas projects.
What's Changed
- Standalone revenue from operations rose by ≈36.6% YoY to ₹52,456 crore from ₹38,400 crore in Q1 FY26.
- Standalone EBITDA margins contracted by 218 basis points YoY to 8.22% from 10.4% due to high input costs.
- The board approved a new alternative fuel initiative, committing ₹561 crore to build four Compressed Biogas plants in the first phase.
Key Takeaways
- Standalone Q1 revenue increased by ≈36.6% YoY to ₹52,456 crore, reflecting sustained passenger vehicle demand.
- EBITDA margin contraction of 218 basis points weighed heavily on profitability, leading standalone net profit down ≈9.65% YoY to ₹3,352 crore.
- The board approved ₹561 crore in capital expenditure for four compressed biogas plants, demonstrating a pivot towards a green-energy ecosystem.
- Rising raw material costs, higher commodity prices, and gas costs were cited as key headwinds that eroded operating margins.
SAHI Perspective
Maruti Suzuki is exhibiting a distinct divergence between volume execution and margin protection. Top-line expansion of ≈36.6% YoY is highly impressive, powered by the newly commissioned plant in Kharkhoda and broad-based demand. However, the compression of operating margins to 8.22% highlights vulnerability to rising raw material and utility costs. The focus on a multi-fuel strategy, including compressed biogas and flex-fuel, will likely mitigate long-term fuel transition risks, but near-term margin restoration remains the key operational priority.
Market Implications
Near-term pressure on the stock is likely due to the earnings miss relative to analyst estimates (EBITDA margin of 8.22% fell short of the estimated 9.8%). However, the strong demand momentum, rising domestic market share to 41.2%, and extremely lean dealer inventory (13 days) indicate robust underlying business health that should support the stock on declines.
Trading Signals
Market Bias: Neutral
Strong volume and top-line growth (revenue up ≈36.6% YoY to ₹52,456 crore) are offset by margin contraction (EBITDA margin down to 8.22%), leading to a net profit decline of ≈9.65% YoY to ₹3,352 crore, making the near-term outlook neutral.
Overweight: Automobile OEMs, Auto Components
Underweight: High-Cost Commodity Consumers
Trigger Factors:
- Raw material cost stabilization
- Scaling up production at the Kharkhoda plant
- Export recovery in key global markets
Time Horizon: Near-term (0-3 months)
Industry Context
The Indian passenger vehicle market continues to see robust volume dispatches, with total quarterly sales growing 29.3% YoY to 682,724 units for Maruti Suzuki. However, margins across the auto sector are facing headwinds from elevated raw material costs, utility expenses, and shipping disruptions. Competitors are also scaling up their product offerings, but Maruti's domestic market share expansion to 41.2% highlights its competitive resilience.
Key Risks to Watch
- Further escalations in commodity prices and utility costs could continue to compress margins.
- Supply-side bottlenecks and geopolitical disruptions worsening shipping times or parts availability.
- Delayed recovery of exports due to global macroeconomic slowdown.
Recent Developments
On July 2, 2026, Prime Minister Narendra Modi and Japan's Prime Minister Sanae Takaichi formally inaugurated Maruti Suzuki's advanced vehicle manufacturing facility at IMT Kharkhoda, Haryana, representing a total projected investment of ₹35,000 crore to scale capacity to 1 million units. Additionally, on June 4, 2026, Maruti Suzuki launched the Wagon R Flex Fuel, India's first flex-fuel passenger car capable of running on ethanol blends up to E100. In July 2026, the company also commissioned a 1 MWh Battery Energy Storage System (BESS) at its Kharkhoda facility.
Closing Insight
Maruti Suzuki's results show that while the company's manufacturing scalability and market share are stronger than ever, persistent inflation in raw materials remains a crucial headwind. Investors should monitor commodity price trends and production efficiency at the new Kharkhoda plant to gauge margin recovery.
High Performance Trading with SAHI.
Disclaimer: This news section may include AI-generated or AI-assisted news, summaries, drafts, or insights. All content is subject to human review before publication. While we aim for accuracy, readers should independently verify information before relying on it.
Open Free AccountRelated
JPMorgan Downgrades Apollo Tyres: Navigating Commodity Headwinds and Sector Re-rating
JPMorgan Bullish on TVS Motor: Target Price Hiked to ₹4,440 as Resilience Outshines Sector Risks
JPMorgan Shifts Stance on Escorts Kubota: Upgrade to Neutral Amid Sector Recalibration
Geopolitical Friction in Hormuz: Oil Majors Flag Costs of Proposed Tolls and India’s Readiness Gaps
Recent
Glenmark Pharma Q1 Consolidated PBT at ₹6.43 Billion vs ₹4.2 Billion YoY
Blue Dart Express Reports Q1 Consolidated Net Profit of ₹88.5 Crore Versus ₹46.9 Crore YoY
Bharat Electronics Gets Additional Defence Orders Valued At ₹847 Crore
Lupin Receives US FDA Approvals For Sugammadex Injection And Diazepam Injection